Thuan Vo, MD
Internal Medicine · Westminster, CANPI 1366434748
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 626 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AstraZeneca at 24.4% of the total. Reporting peaked in 2019 at $2,646 and has fallen 94.8% since, to $137 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 626 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- GSK$1K
- Ironwood Pharmaceuticals, Inc$786
- Amarin Pharma, Inc.$613
- AbbVie$596
- plus $4K from 26 others
What the payments were for
- Food & beverage$11,23399%
- Education$1241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 129 | $2,775 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 84 | $1,177 |
| GSK | 57 | $1,132 |
| Ironwood Pharmaceuticals, Inc | 37 | $786 |
| Amarin Pharma, Inc. | 32 | $613 |
| AbbVie(2 entities) | 46 | $596 |
| Hikma Pharmaceuticals USA | 65 | $563 |
| Amgen | 25 | $535 |
| Astellas Pharma US Inc | 25 | $516 |
| Nestle Healthcare Nutrition Inc. | 18 | $447 |
| Lilly USA, LLC | 19 | $416 |
| Pfizer | 15 | $236 |
| Merck | 8 | $175 |
| Sunovion Pharmaceuticals Inc. | 9 | $174 |
| Johnson & Johnson | 9 | $146 |
| Vanda Pharmaceuticals Inc. | 5 | $132 |
| Novartis | 1 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $115 |
| Esperion Therapeutics, Inc. | 4 | $105 |
| Gilead | 6 | $101 |
| Boehringer Ingelheim | 4 | $101 |
| Sun Pharmaceutical Industries Inc. | 4 | $82 |
| Novo Nordisk | 3 | $67 |
| Sanofi Pasteur Inc. | 2 | $47 |
| Aimmune Therapeutics, Inc. | 2 | $45 |
| Eyevance Pharmaceuticals LLC | 1 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Exact Sciences | 1 | $21 |
| Smith+Nephew | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$121
How this compares
$11,357 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 415 | $227,510 |
| LinzessLinaclotide | 231 | $193,514 |
| JardianceEmpagliflozin | 189 | $172,530 |
| JanuviaSitagliptin Phosphate | 165 | $171,888 |
| CreonLipase/Protease/Amylase | 113 | $156,294 |
| FarxigaDapagliflozin Propanediol | 140 | $155,112 |
| TradjentaLinagliptin | 140 | $120,513 |
| MyrbetriqMirabegron | 163 | $113,085 |
| Dexlansoprazole DrDexlansoprazole | 379 | $112,119 |
| ProliaDenosumab | 56 | $93,370 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 97 | $87,199 |
| RestasisCyclosporine | 93 | $80,239 |
| Cyclosporine | 125 | $72,721 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 84 | $68,130 |
| TrulicityDulaglutide | 56 | $66,419 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon, Restasis, Namzaric | $596 | $449,890456 claims |
| Boehringer IngelheimJardiance, Tradjenta | $101 | $293,043329 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Lokelma, Brilinta | $2,775 | $258,218257 claims |
| MerckJanuvia | $175 | $171,888165 claims |
| Astellas Pharma US IncMyrbetriq | $516 | $113,085163 claims |
| AmgenProlia | $535 | $93,37056 claims |
| GSKTrelegy Ellipta | $1,132 | $87,19997 claims |
| Lilly USA, LLCTrulicity | $416 | $66,41956 claims |
| PfizerEliquis | $236 | $52,97068 claims |
| Aimmune Therapeutics, Inc.Zenpep | $45 | $45,09523 claims |
| Novo NordiskOzempic, Rybelsus | $67 | $41,74736 claims |
| Johnson & JohnsonXarelto | $146 | $23,86518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Westminster
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.